ELAB

PMGC Holdings Inc. (ELAB) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. PMGC Holdings Inc. (formerly Elevai Labs Inc.) operates as a holding company with a diversified portfolio including biopharmaceuticals (Northstrive Biosciences), investment management (PMGC Capital), IT packaging (Pacific Sun), and precision engineering/machining (AGA and SVM). The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The company generated revenue for the first time in the current period ($681,994) compared to zero in Q1 2025, driven by newly acquired subsidiaries (Pacific Sun, AGA, and SVM).
• Acquisition Activity: Completed the acquisition of SVM Machining, Inc. on February 2, 2026, for total consideration of approximately $3.0 million. This significantly increased assets, particularly Property, Plant & Equipment and Intangibles.
• Financing Activity: Raised approximately $14.1 million in net proceeds through four tranches of a Secured Pre-Paid Purchase Equity Line of Credit (ELOC). This increased cash balances significantly but also increased convertible debt and derivative liabilities.
• Expense Growth: Operating expenses increased to $3.6 million from $1.2 million year-over-year, primarily due to consulting fees (including $1.03M in bonuses), professional fees related to acquisitions, and administrative costs for new entities.
• Non-Cash Charges: Significant non-cash losses impacted the bottom line, including a $681,126 loss on the change in fair value of derivative liabilities and $561,922 in finance costs related to the ELOC.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states that the company's substantial accumulated deficit ($25.9M) and recurring net losses raise substantial doubt about its ability to continue as a going concern. Continuation depends on securing additional financing and achieving profitable operations.
• Strategic Focus: Management plans to focus on increasing revenue through PMGC Capital investments, advancing clinical development for Northstrive Biosciences (specifically the EL-22 asset), and pursuing further acquisitions of cash-flow-positive B2B companies.
• Subsequent Events:
  • Established a new subsidiary, NorthStrive Defense Tech LLC, focused on drone and autonomous defense systems.
  • Entered a new $40 million ELOC agreement in April 2026.
  • Completed the acquisition of A&B Aerospace, Inc. in May 2026 for approximately $4.5 million.
• Risks: Key risks include the ability to raise sufficient capital, volatility in derivative liability valuations, integration risks of recent acquisitions, and the success of clinical trials for biotech assets.

Investor Verification Checklist

• Derivative Liability Volatility: Verify the valuation methodology for the $2.5M derivative liability, as changes in fair value significantly impact net income.
• ELOC Terms and Settlement: Review the specific conversion terms, floor prices, and beneficial ownership limitations of the ELOC to understand potential future dilution.
• Acquisition Integration: Assess the revenue contribution and EBITDA performance of the newly acquired SVM and A&B Aerospace entities to determine if they are meeting cash-flow expectations.
• Related Party Transactions: Scrutinize the $1.34M in remuneration paid to key management and related parties (consulting fees and bonuses) relative to the company's cash burn.
• Cash Burn Rate: Monitor the operating cash burn of approximately $3.0M per quarter against the current cash balance of $14.3M to estimate runway without further financing.